RxDoctor Payments Data

Andrew Smith, MD

Family Medicine · Greenwood, SCNPI 1073875464

Payments from drug & device makers

$1,587in general payments, 2019–2025

Across 84 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$393
  • Lilly USA, LLC$279
  • Pfizer$147
  • AstraZeneca$120
  • Abbott$115
  • Bayer$97
  • plus $436 from 14 others

What the payments were for

  • Food & beverage$1,57599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,587 in reported general payments places this provider in the 65th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$10,844
Medicare patients
61
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide169$224,677
FarxigaDapagliflozin Propanediol172$160,113
JardianceEmpagliflozin85$113,693
TrulicityDulaglutide64$95,376
EliquisApixaban117$89,371
MounjaroTirzepatide53$70,170
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$69,337
XareltoRivaroxaban81$61,776
Tresiba Flextouch U-200Insulin Degludec36$26,279
EntrestoSacubitril/Valsartan23$25,304
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$22,703
Aimovig AutoinjectorErenumab-Aooe22$22,416
Soliqua 100-33Insulin Glargine/Lixisenatide14$21,670
MyrbetriqMirabegron32$18,556
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$16,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$393$224,677169 claims
Lilly USA, LLCTrulicity, Mounjaro$279$165,546117 claims
AstraZenecaFarxiga$120$160,113172 claims
PfizerEliquis$147$89,371117 claims
Johnson & JohnsonXarelto$18$61,77681 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$63$21,67014 claims
AbbVieLinzess$95$8,80615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greenwood

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →